Literature DB >> 16482624

Effect of hepatic iron concentration reduction on hepatic fibrosis and damage in rats with cholestatic liver disease.

Gil Peretz1, Gabriela Link, Orit Pappo, Rafael Bruck, Zvi Ackerman.   

Abstract

AIM: To assess the effect of iron reduction after phlebotomy in rats with "normal" hepatic iron concentration (HIC) on the progression of hepatic fibrosis, as a result of bile duct ligation (BDL).
METHODS: Rats underwent phlebotomy before or after sham operation or BDL. Animals undergone only BDL or sham operation served as controls. Two weeks after surgery, indices of hepatic damage and fibrosis were evaluated.
RESULTS: Phlebotomy lowered HIC. Phlebotomy after BDL was associated with body weight increase, lower hepatic weight, less portal hypertension, less periportal necrosis, less portal inflammation, lower hepatic activity index score and higher albumin levels. On the other hand, phlebotomy before BDL was associated with body weight decrease and hepatic activity index score increase. Phlebotomy after sham operation was not associated with any hepatic or systemic adverse effects.
CONCLUSION: Reduction of HIC after induction of liver damage may have beneficial effects in BDL rats. However, iron deficiency could induce impairment of liver function and may make the liver more susceptible to insults like BDL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16482624      PMCID: PMC4066033          DOI: 10.3748/wjg.v12.i2.240

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  55 in total

1.  Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C.

Authors:  Motoyoshi Yano; Hisao Hayashi; Shinya Wakusawa; Fujiko Sanae; Toshikuni Takikawa; Yuhta Shiono; Motohiro Arao; Koji Ukai; Hiroshi Ito; Kazumasa Watanabe; Kentaro Yoshioka
Journal:  Am J Gastroenterol       Date:  2002-01       Impact factor: 10.864

2.  Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease.

Authors:  Francesco S Facchini; Nancy W Hua; Riccardo A Stoohs
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

Review 3.  Iron as a cofactor in chronic hepatitis C infection.

Authors:  C A Sherrington; J K Olynyk
Journal:  Liver       Date:  2002-06

4.  Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial.

Authors:  R J Fontana; J Israel; P LeClair; B F Banner; K Tortorelli; N Grace; R A Levine; G Fiarman; M Thiim; A S Tavill; H L Bonkovsky
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

5.  Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis.

Authors:  J R Jonsson; A D Clouston; Y Ando; L I Kelemen; M J Horn; M D Adamson; D M Purdie; E E Powell
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

6.  Peripheral blood count abnormalities among patients with hepatitis C in the United States.

Authors:  Michael B Streiff; Shruti Mehta; David L Thomas
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

7.  Deferiprone, an oral iron chelator, ameliorates experimental colitis and gastric ulceration in rats.

Authors:  J Ablin; O Shalev; E Okon; F Karmeli; D Rachmilewitz
Journal:  Inflamm Bowel Dis       Date:  1999-11       Impact factor: 5.325

8.  Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection.

Authors:  Stephen Pianko; John G McHutchison; Stuart C Gordon; Shanon Heaton; Zachary D Goodman; Keyur Patel; Cherise M Cortese; Elizabeth M Brunt; Bruce R Bacon; Lawrence M Blatt
Journal:  J Interferon Cytokine Res       Date:  2002-04       Impact factor: 2.607

9.  Chronic hepatitis C is mild in menstruating women.

Authors:  M Sartori; S Andorno; C Rigamonti; E Grossini; G Nicosia; R Boldorini
Journal:  J Gastroenterol Hepatol       Date:  2000-12       Impact factor: 4.029

10.  Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study.

Authors:  Silvia Fargion; Anna Ludovica Fracanzani; Angelo Rossini; Mauro Borzio; Oliviero Riggio; Giovanni Belloni; Franco Bissoli; Roberto Ceriani; Marco Ballarè; Marco Massari; Caterina Trischitta; Pierluigi Fiore; Anna Orlandi; Lorenzo Morini; Michela Mattioli; Silvia Oldani; Bruno Cesana; Gemino Fiorelli
Journal:  Am J Gastroenterol       Date:  2002-05       Impact factor: 10.864

View more
  3 in total

1.  Comparison of the prophylactic effect of silymarin and deferoxamine on iron overload-induced hepatotoxicity in rat.

Authors:  Hossein Najafzadeh; Mohammad Razi Jalali; Hassan Morovvati; Farnaz Taravati
Journal:  J Med Toxicol       Date:  2010-03

2.  Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation.

Authors:  Ann-Kathrin Eisfeld; Rainer Krahl; Nadja Jaekel; Dietger Niederwieser; Haifa Kathrin Al-Ali
Journal:  Am J Blood Res       Date:  2012-11-25

3.  Re: "Protective Role of Silymarin and Deferoxamine against Iron Dextran-Induced Renal Iron Deposition in Male Rats," and "Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model".

Authors:  Safoora Mazaheri; Behjat Alsaadat Moaeidi; Mehdi Nematbakhsh
Journal:  Int J Prev Med       Date:  2014-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.